
Publication|Articles|November 10, 2011
Supplement: Oncology November 2011 Short
The goal of this supplement is to present a comprehensive overview of the major current and emerging treatment options for patients with relapsed and/or refractory multiple myeloma.
Advertisement
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
All-Oral Revumenib Regimen May Show Advantage in Newly Diagnosed AML
2
Blinatumomab/Ponatinib Provides Chemo-Free Option in Ph+ ALL
3
Talquetamab Combo Yields Responses in Multiple Myeloma With True EMD
4
Linvoseltamab Yields High Response in Newly Diagnosed Multiple Myeloma
5


















































































